Biomarkers in renal cell carcinoma: Are we there yet?

por Gulati, Shuchi, Vogelzang, Nicholas J.
Publicado 2021

Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer prevention

por Moyad, Mark A, Vogelzang, Nicholas J
Publicado 2015

An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated w...

por Morgans, Alicia K., Hutson, Thomas, Guan, Alice Kai Dan, Garcia, David, Zhou, Anna, Drea, Edward, Vogelzang, Nicholas J.
Publicado 2022

Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA

por Sartor, Oliver, Hoskin, Peter, Coleman, Robert E., Nilsson, Sten, Vogelzang, Nicholas J., Petrenciuc, Oana, Staudacher, Karin, Thuresson, Marcus, Parker, Christopher
Publicado 2016

CKD-EPI and Cockcroft-Gault Equations Identify Similar Candidates for Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

por Pal, Sumanta K., Ruel, Nora, Villegas, Sergio, Chang, Mark, DeWalt, Kara, Wilson, Timothy G., Vogelzang, Nicholas J., Yuh, Bertram E.
Publicado 2014

Sequential Therapy in Metastatic Renal Cell Carcinoma

por Hirsch, Bradford R., Burke, John M., Agrawal, Manish, Hauke, Ralph J., Hutson, Thomas E., Doshi, Gury, Fleming, Mark T., Vogelzang, Nicholas J.
Publicado 2016

Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era

por Shah, Neil J., Sura, Sneha D., Shinde, Reshma, Shi, Junxin, Singhal, Puneet K., Robert, Nicholas J., Vogelzang, Nicholas J., Perini, Rodolfo F., Motzer, Robert J.
Publicado 2023

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospecti...

por Vogelzang, Nicholas J., Pal, Sumanta K., Ghate, Sameer R., Li, Nanxin, Swallow, Elyse, Peeples, Miranda, Zichlin, Miriam L., Meiselbach, Mark K., Perez, Jose Ricardo, Agarwal, Neeraj
Publicado 2018

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis

por Vogelzang, Nicholas J., Pal, Sumanta K., Ghate, Sameer R., Swallow, Elyse, Li, Nanxin, Peeples, Miranda, Zichlin, Miriam L., Meiselbach, Mark K., Perez, Jose Ricardo, Agarwal, Neeraj
Publicado 2017

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

por Wong, Risa L., Duong, Mai T., Tangen, Catherine M., Agarwal, Neeraj, Cheng, Heather H., Vogelzang, Nicholas J., Hussain, Maha, Thompson, Ian M., Quinn, David I., Yu, Evan Y.
Publicado 2020

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107

por Twardowski, Przemyslaw W., Tangen, Catherine M., Wu, Xiwei, Plets, Melissa R., Plimack, Elizabeth R., Agarwal, Neeraj, Vogelzang, Nicholas J., Wang, Jinhui, Tao, Shu, Thompson, Ian M., Lara, Primo
Publicado 2017

Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III St...

por Synold, Timothy W., Plets, Melissa, Tangen, Catherine M., Heath, Elisabeth I., Palapattu, Ganesh S., Mack, Philip C., Stein, Mark N., Meng, Maxwell V., Lara, Primo, Vogelzang, Nicholas J., Thompson, Ian Murchie, Ryan, Christopher W.
Publicado 2019

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

por Xiao, Yuanyuan, Rabe, Christina, Kowanetz, Marcin, Powles, Thomas, Vogelzang, Nicholas J, Petrylak, Daniel P, Loriot, Yohann, Denker, Mitchell, Nakamura, Rin, Wu, Qun J, Sumiyoshi, Teiko, Boyd, Zachary, Teng, Siew-leng M, Shen, Xiaodong, Fine, Gregg, Chen, Daniel S, Hegde, Priti S
Publicado 2014

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

por Koshkin, Vadim S., Barata, Pedro C., Zhang, Tian, George, Daniel J., Atkins, Michael B., Kelly, William J., Vogelzang, Nicholas J., Pal, Sumanta K., Hsu, JoAnn, Appleman, Leonard J., Ornstein, Moshe C., Gilligan, Timothy, Grivas, Petros, Garcia, Jorge A., Rini, Brian I.
Publicado 2018

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

por Gulley, James L., Borre, Michael, Vogelzang, Nicholas J., Ng, Siobhan, Agarwal, Neeraj, Parker, Chris C., Pook, David W., Rathenborg, Per, Flaig, Thomas W., Carles, Joan, Saad, Fred, Shore, Neal D., Chen, Liddy, Heery, Christopher R., Gerritsen, Winald R., Priou, Frank, Langkilde, Niels C., Novikov, Andrey, Kantoff, Philip W.
Publicado 2019

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase II...

por Unger, Joseph M., Griffin, Katherine, Donaldson, Gary W., Baranowski, Karen M., Good, Margorie J., Reburiano, Eunicia, Hussain, Maha, Monk, Paul J., Van Veldhuizen, Peter J., Carducci, Michael A., Higano, Celestia S., Lara, Primo N., Tangen, Catherine M., Quinn, David I., Wade, James L., III, Vogelzang, Nicholas J., Thompson, Ian M., Jr, Moinpour, Carol M.
Publicado 2018

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-res...

por Autio, Karen A, Higano, Celestia S, Nordquist, Luke, Appleman, Leonard J, Zhang, Tian, Zhu, Xin-Hua, Babiker, Hani, Vogelzang, Nicholas J, Prasad, Sandip M, Schweizer, Michael T, Madan, Ravi A, Billotte, Stephane, Cavazos, Nora, Bogg, Orlaith, Li, Ray, Chan, Kam, Cho, Helen, Kaneda, Megan, Wang, I-Ming, Zheng, Jenny, Tang, Szu-Yu, Hollingsworth, Robert, Kern, Kenneth A, Petrylak, Daniel P
Publicado 2023

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

por Higano, Celestia S., Armstrong, Andrew J., Sartor, A. Oliver, Vogelzang, Nicholas J., Kantoff, Philip W., McLeod, David G., Pieczonka, Christopher M., Penson, David F., Shore, Neal D., Vacirca, Jeffrey, Concepcion, Raoul S., Tutrone, Ronald F., Nordquist, Luke T., Quinn, David I., Kassabian, Vahan, Scholz, Mark C., Harmon, Matt, Tyler, Robert C., Chang, Nancy N., Tang, Hong, Cooperberg, Matthew R.
Publicado 2019

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

por Sartor, Oliver, Armstrong, Andrew J., Ahaghotu, Chiledum, McLeod, David G., Cooperberg, Matthew R., Penson, David F., Kantoff, Philip W., Vogelzang, Nicholas J., Hussain, Arif, Pieczonka, Christopher M., Shore, Neal D., Quinn, David I., Small, Eric J., Heath, Elisabeth I., Tutrone, Ronald F., Schellhammer, Paul F., Harmon, Matthew, Chang, Nancy N., Sheikh, Nadeem A., Brown, Bruce, Freedland, Stephen J., Higano, Celestia S.
Publicado 2020

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

por Abida, Wassim, Patnaik, Akash, Campbell, David, Shapiro, Jeremy, Bryce, Alan H., McDermott, Ray, Sautois, Brieuc, Vogelzang, Nicholas J., Bambury, Richard M., Voog, Eric, Zhang, Jingsong, Piulats, Josep M., Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Higano, Celestia S., Krieger, Laurence E., Sternberg, Cora N., Watkins, Simon P., Despain, Darrin, Simmons, Andrew D., Loehr, Andrea, Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon
Publicado 2020